CANbridge Pharmaceuticals Inc. (1228.HK)

HKD 0.16

(0.65%)

Operating Expenses Summary of CANbridge Pharmaceuticals Inc.

  • CANbridge Pharmaceuticals Inc.'s latest annual operating expenses in 2023 was 64.16 Million CNY , down -13.87% from previous year.
  • CANbridge Pharmaceuticals Inc.'s latest quarterly operating expenses in 2024 Q2 was 124.34 Million CNY , down 0.0% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported a annual operating expenses of 498.4 Million CNY in annual operating expenses 2022, down -26.0% from previous year.
  • CANbridge Pharmaceuticals Inc. reported a annual operating expenses of 673.51 Million CNY in annual operating expenses 2021, up 183.03% from previous year.
  • CANbridge Pharmaceuticals Inc. reported a quarterly operating expenses of 124.34 Million CNY for 2024 Q1, up 23.6% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported a quarterly operating expenses of 102.32 Million HKD for 2023 Q3, down -14.86% from previous quarter.

Annual Operating Expenses Chart of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Historical Annual Operating Expenses of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Year Operating Expenses Operating Expenses Growth
2023 64.16 Million CNY -13.87%
2022 498.4 Million CNY -26.0%
2021 673.51 Million CNY 183.03%
2020 237.97 Million CNY 72.68%
2019 137.81 Million CNY 0.0%

Peer Operating Expenses Comparison of CANbridge Pharmaceuticals Inc.

Name Operating Expenses Operating Expenses Difference
Uni-Bio Science Group Limited 325.05 Million HKD 80.26%
CK Life Sciences Int'l., (Holdings) Inc. 739.25 Million HKD 91.32%